(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/040428 A2

(51) International Patent Classification[7]: C12Q 1/68, C12N 15/54, A61K 31/7088, C12N 15/11, C07K 16/40

(21) International Application Number: PCT/US2004/035284

(22) International Filing Date: 22 October 2004 (22.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/513,888	23 October 2003 (23.10.2003)	US
60/542,373	6 February 2004 (06.02.2004)	US
60/554,758	19 March 2004 (19.03.2004)	US
60/560,524	8 April 2004 (08.04.2004)	US
60/578,323	9 June 2004 (09.06.2004)	US
60/583,503	28 June 2004 (28.06.2004)	US
60/605,243	26 August 2004 (26.08.2004)	US

(71) Applicant *(for all designated States except US)*: **ILLUMIGEN BIOSCIENCES, INC.** [US/US]; 2203 Airport Way South, Suite 450, Seattle, WA 98134 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **IADONATO, Shawn, P.** [US/US]; 421 31st Avenue, Seattle, WA 98122 (US). **MAGNESS, Charles, L.** [US/US]; P.O. Box 51182, Seattle, WA 98115 (US). **ROSENBERG, Gary** [US/US]; 23519 23rd Avenue SE, Bothell, WA 98021 (US). **SCHERER, Christina, A.** [US/US]; 1837 12th Avenue W, Seattle, WA 98119 (US).

(74) Agents: **POTTER, Jane, E., R.** et al.; Davis Wright Tremaine LLP, 2600 Century Square, 1501 Fourth Avenue, Seattle, WA 98101-1688 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

[Continued on next page]

(54) Title: DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, OAS1



(57) Abstract: A method for detecting a mutation related to the gene encoding OAS 1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS 1, including antisense oligonucleotides, methods, and compositions specific for human OASI, are also provided.

WO 2005/040428 A2

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.